Skip to content

Advertisement

  • Oral presentation
  • Open Access

Medium-term results after implant of a new generation stentless aortic prosthesis: hemodynamic performance of medtronic 3F® stentless equine pericardial aortic valve

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of Cardiothoracic Surgery20138 (Suppl 1) :O320

https://doi.org/10.1186/1749-8090-8-S1-O320

  • Published:

Keywords

  • Aortic Valve
  • Endocarditis
  • Thromboembolic Event
  • Aortic Valve Disease
  • Cross Clamp Time

Background

Aim of this study was to evaluate the clinical and hemodynamic results at 5 years of Medtronic 3F® stentless equine pericardial aortic valve.

Methods

Between March 2007 and December 2012 a total of 120 consecutive patients affected by aortic valve disease received a 3F valve at our unit. The size ranged between 21 and 29, with prevalence of 23 and 25 implants .Mean age at operation was 75,6±8,0 years, 54% were males, the mean logistic EuroScore was 8,7±5,2 and 47% received concomitant procedures. For isolated replacements the mean ECC time was 90’±10’, Cross Clamp time 72’±8’.In 12 pts the aortic prosthesis was included in a Dacron tube straight graft for a Bentall operation.

Results

Early mortality in isolated AVR was 2,1% and 3,1% in the entire group. There have been 6 late all-causes deaths (5,6%) ,with a survival of 90% at 5 yrs. 91% of patients are in NYHA class I or II. Actuarial freedom from reoperation for structural deterioration is 100% at 5 years. Freedom from endocarditis and thromboembolic events was 96% and 99% respectively. The 72 patients evaluated under exercise at 75w protocol showed a moderate increase in the MPG (from 7,8±3,3mmHg to 11,6±4.0mmHg) for the entire series at five years follow up.

Conclusions

The 3F valve shows excellent hemodynamics, durability and freedom from structural deterioration at 5 yrs follow-up. Freedom from endocarditis and thromboembolic events looks satisfactory. Longer follow-up times are needed for a better evaluation of this interesting new generation of user friendly aortic valve substitute.

Authors’ Affiliations

(1)
Cardiac Surgery, Hesperia Hospital, Modena, Italy

Copyright

© Stefanelli et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement